P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler
Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Ca...
Gespeichert in:
Veröffentlicht in: | Thorax 2021-02, Vol.76 (Suppl 1), p.A189-A190 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A190 |
---|---|
container_issue | Suppl 1 |
container_start_page | A189 |
container_title | Thorax |
container_volume | 76 |
creator | Borenius, K Vartiainen, V Takala, A Haikarainen, J Parker, G Paronen, N Haahtela, T |
description | Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e. Still, limited data is available on CO2FP and Life Cycle Assessment (LCA) of different types of DPIs.We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH). In-depth data collection from Orion in-house data, suppliers, and reference databases was conducted in 2019. Analyses were performed by ISO14001:2015 and 9001:2015 certified Carbon Footprint Ltd.The total CTG life cycle emissions for one EH (average) was 0.588 kg CO2e (range 0.514–0.664 kg). Emissions from manufacture accounted for 60% (range 54–65%). In comparison, emissions from distribution accounted for less than 2%, indicating that most potential for improvement lies in manufacture processes.Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI.Abstract P185 Figure 1 |
doi_str_mv | 10.1136/thorax-2020-BTSabstracts.330 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2479618855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479618855</sourcerecordid><originalsourceid>FETCH-LOGICAL-b765-3bfef01b293b9bf437f0dfb4e6f5d7cf323871585022ffbbe7e0c2af59f3d2223</originalsourceid><addsrcrecordid>eNpN0MlOwzAQgGELgURZ3sESXF28xHZyhIpNqgQSvVt2MqapkrjYbqE3LrwoT0JQOXCay68ZzYfQJaNTxoS6yssQ7QfhlFNys3ixLuVo65ymQtADNGGFKonglTpEE0oLSpTQ6hidpLSilJaM6Qnqn1kpvz-_5q0HXO_qDrBNCVLqYcjYDg2uo206IDmQ12i3Y2SjCwP2IeR1bMcoeGxxv-ly24QEOEKCuA1txE3c4XV4byDidljaDuIZOvK2S3D-N0_R4u52MXsg86f7x9n1nDitJBHOg6fM8Uq4yvlCaE8b7wpQXja69oKLUjNZSsq5986BBlpz62XlRcM5F6foYr92HcPbBlI2q7CJw3jR8EJXipWllGOl95XrV2Z8pbdxZxg1v7RmT2t-ac1_WjPSih_sBXVy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479618855</pqid></control><display><type>article</type><title>P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler</title><source>Alma/SFX Local Collection</source><creator>Borenius, K ; Vartiainen, V ; Takala, A ; Haikarainen, J ; Parker, G ; Paronen, N ; Haahtela, T</creator><creatorcontrib>Borenius, K ; Vartiainen, V ; Takala, A ; Haikarainen, J ; Parker, G ; Paronen, N ; Haahtela, T</creatorcontrib><description>Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e. Still, limited data is available on CO2FP and Life Cycle Assessment (LCA) of different types of DPIs.We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH). In-depth data collection from Orion in-house data, suppliers, and reference databases was conducted in 2019. Analyses were performed by ISO14001:2015 and 9001:2015 certified Carbon Footprint Ltd.The total CTG life cycle emissions for one EH (average) was 0.588 kg CO2e (range 0.514–0.664 kg). Emissions from manufacture accounted for 60% (range 54–65%). In comparison, emissions from distribution accounted for less than 2%, indicating that most potential for improvement lies in manufacture processes.Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI.Abstract P185 Figure 1</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thorax-2020-BTSabstracts.330</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Asthma ; Carbon footprint ; Emissions ; Inhalers ; Life cycles</subject><ispartof>Thorax, 2021-02, Vol.76 (Suppl 1), p.A189-A190</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Borenius, K</creatorcontrib><creatorcontrib>Vartiainen, V</creatorcontrib><creatorcontrib>Takala, A</creatorcontrib><creatorcontrib>Haikarainen, J</creatorcontrib><creatorcontrib>Parker, G</creatorcontrib><creatorcontrib>Paronen, N</creatorcontrib><creatorcontrib>Haahtela, T</creatorcontrib><title>P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler</title><title>Thorax</title><description>Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e. Still, limited data is available on CO2FP and Life Cycle Assessment (LCA) of different types of DPIs.We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH). In-depth data collection from Orion in-house data, suppliers, and reference databases was conducted in 2019. Analyses were performed by ISO14001:2015 and 9001:2015 certified Carbon Footprint Ltd.The total CTG life cycle emissions for one EH (average) was 0.588 kg CO2e (range 0.514–0.664 kg). Emissions from manufacture accounted for 60% (range 54–65%). In comparison, emissions from distribution accounted for less than 2%, indicating that most potential for improvement lies in manufacture processes.Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI.Abstract P185 Figure 1</description><subject>Asthma</subject><subject>Carbon footprint</subject><subject>Emissions</subject><subject>Inhalers</subject><subject>Life cycles</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpN0MlOwzAQgGELgURZ3sESXF28xHZyhIpNqgQSvVt2MqapkrjYbqE3LrwoT0JQOXCay68ZzYfQJaNTxoS6yssQ7QfhlFNys3ixLuVo65ymQtADNGGFKonglTpEE0oLSpTQ6hidpLSilJaM6Qnqn1kpvz-_5q0HXO_qDrBNCVLqYcjYDg2uo206IDmQ12i3Y2SjCwP2IeR1bMcoeGxxv-ly24QEOEKCuA1txE3c4XV4byDidljaDuIZOvK2S3D-N0_R4u52MXsg86f7x9n1nDitJBHOg6fM8Uq4yvlCaE8b7wpQXja69oKLUjNZSsq5986BBlpz62XlRcM5F6foYr92HcPbBlI2q7CJw3jR8EJXipWllGOl95XrV2Z8pbdxZxg1v7RmT2t-ac1_WjPSih_sBXVy</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Borenius, K</creator><creator>Vartiainen, V</creator><creator>Takala, A</creator><creator>Haikarainen, J</creator><creator>Parker, G</creator><creator>Paronen, N</creator><creator>Haahtela, T</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202102</creationdate><title>P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler</title><author>Borenius, K ; Vartiainen, V ; Takala, A ; Haikarainen, J ; Parker, G ; Paronen, N ; Haahtela, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b765-3bfef01b293b9bf437f0dfb4e6f5d7cf323871585022ffbbe7e0c2af59f3d2223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Asthma</topic><topic>Carbon footprint</topic><topic>Emissions</topic><topic>Inhalers</topic><topic>Life cycles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borenius, K</creatorcontrib><creatorcontrib>Vartiainen, V</creatorcontrib><creatorcontrib>Takala, A</creatorcontrib><creatorcontrib>Haikarainen, J</creatorcontrib><creatorcontrib>Parker, G</creatorcontrib><creatorcontrib>Paronen, N</creatorcontrib><creatorcontrib>Haahtela, T</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borenius, K</au><au>Vartiainen, V</au><au>Takala, A</au><au>Haikarainen, J</au><au>Parker, G</au><au>Paronen, N</au><au>Haahtela, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler</atitle><jtitle>Thorax</jtitle><date>2021-02</date><risdate>2021</risdate><volume>76</volume><issue>Suppl 1</issue><spage>A189</spage><epage>A190</epage><pages>A189-A190</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><abstract>Dry powder inhalers (DPIs) have about 20-fold lower carbon footprint (CO2FP) than metered dose inhalers (MDIs) with estimates of CO2FP between 1.5 and 6 kg CO2e for a 200-dose DPI. GSK’s Carbon Trust-verified analysis including Relvar and Seretide Accuhaler is about 1 kg CO2e/inhaler, and Product Carbon Footprint analysis of Spiriva Respimat 0.780 kg CO2e. Still, limited data is available on CO2FP and Life Cycle Assessment (LCA) of different types of DPIs.We conducted a Cradle-to-Grave (CTG) CO2FP analysis and LCA of four different Easyhaler® (EH) products available for the treatment of asthma and COPD (budesonide-formoterol; salmeterol-fluticasone; salbutamol, and formoterol EH). In-depth data collection from Orion in-house data, suppliers, and reference databases was conducted in 2019. Analyses were performed by ISO14001:2015 and 9001:2015 certified Carbon Footprint Ltd.The total CTG life cycle emissions for one EH (average) was 0.588 kg CO2e (range 0.514–0.664 kg). Emissions from manufacture accounted for 60% (range 54–65%). In comparison, emissions from distribution accounted for less than 2%, indicating that most potential for improvement lies in manufacture processes.Patients with asthma or COPD, and treating physicians alike, are increasingly aware of climate change and this affects even their treatment choices. When considering the climate impact of inhalation therapy, DPIs, like EH, have a minimal carbon footprint compared with MDI.Abstract P185 Figure 1</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/thorax-2020-BTSabstracts.330</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0040-6376 |
ispartof | Thorax, 2021-02, Vol.76 (Suppl 1), p.A189-A190 |
issn | 0040-6376 1468-3296 |
language | eng |
recordid | cdi_proquest_journals_2479618855 |
source | Alma/SFX Local Collection |
subjects | Asthma Carbon footprint Emissions Inhalers Life cycles |
title | P185 Life cycle assessment and cradle-to-grave carbon footprint of a multidose reservoir dry powder inhaler |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A54%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P185%E2%80%85Life%20cycle%20assessment%20and%20cradle-to-grave%20carbon%20footprint%20of%20a%20multidose%20reservoir%20dry%20powder%20inhaler&rft.jtitle=Thorax&rft.au=Borenius,%20K&rft.date=2021-02&rft.volume=76&rft.issue=Suppl%201&rft.spage=A189&rft.epage=A190&rft.pages=A189-A190&rft.issn=0040-6376&rft.eissn=1468-3296&rft_id=info:doi/10.1136/thorax-2020-BTSabstracts.330&rft_dat=%3Cproquest_bmj_p%3E2479618855%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479618855&rft_id=info:pmid/&rfr_iscdi=true |